dronedarone
DISEASE INTERVENTION COMPARISON RESULTS
Am J Cardiol. 2012 Aug 15;110(4):607-13. doi: 10.1016/j.amjcard.2012.04.034. Epub 2012 May 19 Meta-Analysis
IN atrial fibrillation, paroxysmal, persistent, heart failure The Use of
dronedarone
As Treatment, Chronic
Is worse Than
placebo
To increase all-cause and cardiovascular mortality and increase heart failure exacerbations
N Engl J Med. 2009 Feb 12;360(7):668-78 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009 The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 21 months cardiovascular deaths (2.7% dronedarone VS 3.9% placebo) and hospitalizations (26.9% dronedarone VS 33.4% placebo). No significant difference in overall mortality.
Circulation. 2009 Sep 29;120(13):1174-80 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009, subordinated publication The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce annual risk of stroke (all types): 1.2% dronedarone VS 1.8% placebo
N Engl J Med. 2011 Dec 15;365(24):2268-76 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, persistent, rate control, pharmacologic, Study ID: PALLAS 2011 The Use of
dronedarone
As Treatment, Chronic
Is worse Than
placebo
To modify cardiovascular events: dronedarone increased deaths from cardiovascular causes (HR 2.1), stroke (HR 2.3) and heart failure (HR 1.8)
J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605 Study type to be defined
IN atrial fibrillation, recent-onset, persistent, StudyID: DYONISOS 2010 The Use of
dronedarone
As Treatment, Chronic
Is worse Than
amiodarone
To reduce, at 6 months, AF recurrence. Dronedarone had slightly fewer deaths and adverse events but differences were not significants
J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95 Meta-Analysis
IN atrial fibrillation, recurrent The Use of
dronedarone
As Treatment, Chronic
Is worse Than
amiodarone, placebo
To prevent AF recurrences: OR 0.79 non-significant VS placebo, OR amiodarone VS dronedarone 0.49 significant) However, amiodarone had more withdrawals due to side effects (OR 1.81 significant)
N Engl J Med. 2008 Jun 19;358(25):2678-87 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic, StudyID: ANDROMEDA 2008 The Use of
dronedarone
As Treatment, Chronic
Is worse Than
placebo
To mortality: it increased at 2 months (8.1% dronedarone VS 3.8% placebo), mainly because worsening heart failure
Eur Heart J. 2003 Aug;24(16):1481-7 Randomized Controlled Trial
IN StudyID: DAFNE 2003, atrial fibrillation, persistent The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
N Engl J Med. 2007 Sep 6;357(10):987-99 Randomized Controlled Trial, Multicenter Study
IN StudyID: EURIDIS ADONIS 2004, atrial fibrillation The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 1 year recurrence of AF (% of recurrences ?). Effect on mortality, stroke, heart failure ?